Factor IX Complex (Human)
- Generic Name
- Factor IX Complex (Human)
- Brand Names
- Profilnine
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 37224-63-8
- Unique Ingredient Identifier
- FW411QXD5M
- Background
Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of F...
- Indication
Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy.
- Associated Conditions
- Bleeding, Hemorrhage, Intracranial Hemorrhages
- Associated Therapies
- Perioperative bleeding management therapy
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Institut de cancérologie Strasbourg Europe
- Target Recruit Count
- 46
- Registration Number
- NCT06725368
- Locations
- 🇫🇷
Centre hospitalier Régional de Metz-Thionville, Ars-Laquenexy, France
🇫🇷Centre Hospitalier de Colmar, Colmar, France
🇫🇷Institut de cancérologie Strasbourg Europe, Strasbourg, France
Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-10-04
- Target Recruit Count
- 650
- Registration Number
- NCT06627218
- Locations
- 🇨🇳
Department of Emergency medicine, Second Affiliated Hospital, School of Medicine& Institute of Emergency medicine, Zhejiang University,, Hangzhou, Zhejiang, China
Coagulation in Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 400
- Registration Number
- NCT05667805
- Locations
- 🇦🇹
General Hospital of the Medical University of Vienna, Vienna, Austria
Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5480
- Registration Number
- NCT05548777
- Locations
- 🇺🇸
Research Site, Agoura Hills, California, United States
ZEPLAST- PED: ZEro_PLASma Trial in Small Infants Undergoing Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- IRCCS Policlinico S. Donato
- Target Recruit Count
- 40
- Registration Number
- NCT04434001
- Locations
- 🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, MI, Italy
CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients
- Conditions
- Interventions
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Target Recruit Count
- 18
- Registration Number
- NCT02777424
- Locations
- 🇫🇷
CHU de Lille, Lille, France
🇫🇷Fondation Ophtalmologique Adolphe de Rothschild (FOR), Paris, France
🇫🇷CHU de NANCY, Nancy, France
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT02622321
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Boston Childrens Hospital, Boston, Massachusetts, United States
🇯🇵Hospital of the University of Occupational and Environmental Health,Japan, Kitakyushu-shi, Japan
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 106
- Registration Number
- NCT02557672
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
PCC and Fibrinogen Compared With FFP in PPH
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Helsinki University Central Hospital
- Registration Number
- NCT01910675
- Locations
- 🇫🇮
Maternity Hospital, Helsinki University Central Hospital, Helsinki, Uusimaa, Finland
Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass
- Conditions
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Emory University
- Target Recruit Count
- 24
- Registration Number
- NCT01352143
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.